Jan 09, 2024 / 04:15PM GMT
Rachel Marie Vatnsdal Olson - JPMorgan Chase & Co, Research Division - Analyst
Perfect. Good morning, everyone. This is Rachel Vatnsdal from the life science tools and diagnostics team here at JPMorgan. I'm joined on stage by Marc Casper, CEO of Thermo Fisher. So as we typically do, this is going to be a 40-minute session. First half will be roughly 20 minutes of presentation, followed by 20 minutes of Q&A. If you do have questions, feel free to either submit them via the portal or you can ping me directly.
With that, Marc, I'll pass it off to you.
Marc N. Casper - Thermo Fisher Scientific Inc. - Chairman, President & CEO
Rachel, thank you. Nice to see everybody here in San Francisco. Great to be back at the JPMorgan conference. So the time goes quickly. A year ago, I'm reflecting back on being in front of this group right here in this ballroom and thinking about the year ahead for 2023. And I think the industry, and certainly ourselves as well expected that our industry would see moderating growth in 2023 after several years of
Thermo Fisher Scientific Inc at JPMorgan Healthcare Conference Transcript
Jan 23, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers